No Prescription |
 |
 | ||
|
Micardis Generic Telmisartan |
|
| ||
No Prescription » Prescription Drugs 11 » Micardis Generic Telmisartan This drug is used to treat high blood pressure (hypertension). High blood pressure reduction helps prevent strokes heart attacks and kidney problems. This drug works by blocking the hormone angiotensin thereby relaxing blood vessels causing them to widen. Telmisartan belongs to a class of drugs called angiotensin receptor blockers. Buy Micardis Generic Telmisartan and other Prescription Drugs 11 products online at Medstore. Buy Online at Medstore - Click Here!
About Micardis Generic Telmisartan: Product Type: Prescription Drugs 11 Micardis ( Generic Telmisartan ) Micardis (Generic Telmisartan) Generic Telmisartan 80mg Generic Telmisartan Micardis
View more Prescription Drugs 11 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
